Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Decreases By 5.9%

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 51,300 shares, a decline of 5.9% from the June 30th total of 54,500 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average daily volume of 8,800 shares, the days-to-cover ratio is presently 5.8 days.

Institutional Investors Weigh In On Eterna Therapeutics

Institutional investors have recently modified their holdings of the business. Lake Street Advisors Group LLC bought a new stake in shares of Eterna Therapeutics in the fourth quarter valued at about $933,000. Vanguard Group Inc. boosted its position in shares of Eterna Therapeutics by 30.6% in the third quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock valued at $54,000 after acquiring an additional 5,830 shares during the period. Sippican Capital Advisors raised its stake in Eterna Therapeutics by 92.3% in the fourth quarter. Sippican Capital Advisors now owns 54,050 shares of the company’s stock valued at $97,000 after purchasing an additional 25,950 shares in the last quarter. Finally, Avidian Wealth Solutions LLC acquired a new position in Eterna Therapeutics in the first quarter valued at about $36,000. Institutional investors own 70.55% of the company’s stock.

Eterna Therapeutics Trading Down 0.4 %

ERNA stock opened at $1.81 on Wednesday. The company has a debt-to-equity ratio of 3.03, a current ratio of 0.79 and a quick ratio of 0.79. The company has a fifty day moving average price of $1.92 and a two-hundred day moving average price of $1.93. Eterna Therapeutics has a one year low of $0.84 and a one year high of $2.91. The stock has a market cap of $9.77 million, a price-to-earnings ratio of -0.42 and a beta of 4.49.

Eterna Therapeutics (NASDAQ:ERNA) last announced its earnings results on Tuesday, May 14th. The company reported ($1.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.